Cinemark - CNK Stock Forecast, Price & News

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cinemark in the last year. There are currently 2 sell ratings, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CNK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CNK, but not buy additional shares or sell existing shares.
View CNK analyst ratings or view top-rated stocks.

8 equities research analysts have issued 1 year price targets for Cinemark's stock. Their CNK share price forecasts range from $9.00 to $22.00. On average, they anticipate the company's stock price to reach $15.56 in the next twelve months. This suggests a possible upside of 25.7% from the stock's current price.
View analysts price targets for CNK or view top-rated stocks among Wall Street analysts.

Cinemark's stock was trading at $8.66 at the start of the year. Since then, CNK stock has increased by 43.0% and is now trading at $12.38.
View the best growth stocks for 2023 here.

Cinemark saw a increase in short interest in the month of December. As of December 30th, there was short interest totaling 24,720,000 shares, an increase of 6.0% from the December 15th total of 23,310,000 shares. Based on an average daily trading volume, of 3,600,000 shares, the days-to-cover ratio is currently 6.9 days. Currently, 22.8% of the company's stock are sold short.
View Cinemark's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Friday, February 24th 2023.
View our CNK earnings forecast.

Cinemark Holdings, Inc. (NYSE:CNK) released its earnings results on Friday, November, 4th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.01. The company had revenue of $650.40 million for the quarter, compared to the consensus estimate of $616.20 million. Cinemark had a negative trailing twelve-month return on equity of 27.93% and a negative net margin of 6.59%.

295 employees have rated Cinemark Chief Executive Officer Mark Zoradi on Glassdoor.com. Mark Zoradi has an approval rating of 73% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cinemark investors own include Pfizer (PFE), Carnival Co. & (CCL), AT&T (T), Wells Fargo & Company (WFC), AMC Entertainment (AMC), Southwest Airlines (LUV), Tesla (TSLA), Exxon Mobil (XOM), Delta Air Lines (DAL) and Intel (INTC).

Cinemark trades on the New York Stock Exchange (NYSE) under the ticker symbol "CNK."

Cinemark's stock is owned by many different institutional and retail investors. Top institutional shareholders include Wolverine Asset Management LLC (0.15%), Assenagon Asset Management S.A. (0.14%), New York State Teachers Retirement System (0.09%), New York State Common Retirement Fund (0.06%), Yousif Capital Management LLC (0.06%) and Comerica Bank (0.05%). Insiders that own company stock include Enrique Senior, Lee Roy Mitchell, Mark Zoradi, Michael Cavalier, Valmir Fernandes and Ximena G Humrichouse.
View institutional ownership trends.

Shares of CNK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CNK stock can currently be purchased for approximately $12.38.

Cinemark (NYSE:CNK) has a market capitalization of $1.49 billion and generates $1.51 billion in revenue each year. The company earns $-422,780,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis.

The company employs 16,000 workers across the globe.

Cinemark's mailing address is 3900 DALLAS PARKWAY, PLANO TX, 75093. The official website for the company is www.cinemark.com. The company can be reached via phone at (972) 665-1000, via email at investors@cinemark.com, or via fax at 972-665-1008.